Financial & insurance assistance

At Biogen, our goal is for everyone to get the support they need so they can afford their brand-name Tecfidera® (dimethyl fumarate). We can work with you to understand your insurance coverage and medication cost, and explore financial assistance options for your treatment.

Understanding your insurance

Biogen Support Coordinators will work with you and your insurance company to explain coverage options and costs, including guiding you through the Prior Authorization process. They can also explain complicated insurance information and changes. For example, if your specialty pharmacy switches you from TECFIDERA to a generic therapy, a Biogen Support Coordinator can assist you and help you find resources and solutions.

Finding financial assistance

Biogen Support Coordinators can also help identify potential options for financial assistance with your relapsing MS medication. If you are:

  • Commercially insured: if you’re eligible, the Biogen Copay Program could lower your medication cost to as little as $0*
  • Government insured: we can check to see if you are eligible for alternative government insurance programs
  • Uninsured or underinsured: we can research other possible financial assistance available to you
Do you have questions
about the cost of
brand-
name TECFIDERA?

Call a Biogen Support Coordinator at 1-800-456-2255, Monday-Friday from 8:30 AM to 8 PM ET. Hablamos español.

*Depending on your income or, in some cases, if your medication is obtained from an
out-of-network provider, there may be an annual cap that limits the amount of assistance that you can receive over one year. Federal and state laws and other factors may prevent or otherwise restrict eligibility. People covered by Medicare, Medicaid, the VA/DoD, or any other federal plans are not eligible to enroll. You are eligible to enroll in the Biogen Copay Program for as long as it is offered and you are treated with a Biogen relapsing MS medication. The Biogen Copay Program is no longer available for TECFIDERA patients in the states of Massachusetts and California.